Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jul:39:5-9.
doi: 10.1016/j.seizure.2016.01.008. Epub 2016 Jan 12.

Intravenous lacosamide in clinical practice-Results from an independent registry

Nicolas Lang  1 , Max Lange  2 , Friedhelm C Schmitt  3 , Monika Bös  4 , Yvonne Weber  5 , Stefan Evers  6 , Lothar Burghaus  7 , Christoph Kellinghaus  8 , Susanne Schubert-Bast  9 , Julian Bösel  10 , Thorsten Lammers  11 , Michael Sabolek  12 , Andreas van Baalen  13 , Rainer Dziewas  14 , Andrea Kraft  15 , Susanne Ruf  16 , Ulrich Stephani  13
Affiliations
Free article
Clinical Trial

Intravenous lacosamide in clinical practice-Results from an independent registry

Nicolas Lang et al. Seizure. 2016 Jul.
Free article

Abstract

Purpose: This non-interventional study was conducted to evaluate the efficacy and tolerability of intravenous lacosamide (LCM-iv) under routine conditions in daily clinical practice as a prospective registry.

Methods: Patients with any type of seizure or epilepsy syndrome were recruited in 16 neurological and neuropediatric centers in Germany if the treating physician decided to administer LCM-iv for any reason. Observation time per patient was 10 days with daily documentation of LCM-iv administration, type and frequency of seizures, currently used drugs and doses, and adverse events. Treatment efficacy, tolerability, and handling of LCM-iv were assessed using a five-step scale.

Results: In 119 patients treating physicians classified epilepsies as focal in 66.1% and generalized in 17.4% (16.5% unclassifiable). Most common etiologies of seizures were tumors (36.1%) and cerebrovascular diseases (21.8%). Reasons for LCM-iv treatment included preparation for surgery (25.2%), convulsive (24.4%) and non-convulsive (18.5%) status epilepticus (SE), series of seizures (16.0%), gastrointestinal causes (5.9%), and acute seizures (4.2%). The median dose of LCM-iv was 300mg per day. In 45 of 64 patients (70.3%) with SE or series of seizures, epileptic activity ceased during observation time. Five patients showed abnormalities in ECG prior to the infusion and one patient afterwards, but during infusion no abnormalities were reported. Treating physicians rated efficacy and tolerability as very good or good in 77.6% and 93.1% of patients, respectively.

Conclusions: This large and independent multicenter registry on the use of LCM-iv in clinical practice demonstrates that LCM-iv is well-tolerated and highly efficacious when given in emergency situations, including patients experiencing SE. It is advisable to perform an electrocardiogram prior to LCM-iv administration.

Keywords: Efficacy; Epilepsy; Lacosamide iv; Seizure; Status epilepticus; Tolerability.

PubMed Disclaimer

MeSH terms